Good Session this morning. Most of the questions focused around pricing for Colostat - $50 is the projected target which could rise if approaching a health fund that currently uses Colonoscopy for screening. Europe market given the current situation - unchanged. Cash position - no plans for any future fund raising, sufficient cash for purposes.
All in all a well timed opportunity to speak with investors, especially with all the uncertaintly swirling around at the moment. And, for me at least, shows that the management is sensitive to the SP and will take measures to support it.
Ann: Rhythm Biosciences - Investor Webinar Presentation, page-6
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.34M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 11.0¢ | $2.291K | 20.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 23335 | 3 |
View Market Depth
| Last trade - 11.54am 08/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |